Warning! GuruFocus detected
2 Severe warning signs
with BH3.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
PTC Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69366J2006
Share Class Description:
FRA:BH3: Ordinary SharesDescription
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.46 | |||||
| Equity-to-Asset | -0.64 | |||||
| Debt-to-Equity | -2.25 | |||||
| Debt-to-EBITDA | -20.51 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.42 | |||||
| Beneish M-Score | -3.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.2 | |||||
| 3-Year EBITDA Growth Rate | 33 | |||||
| 3-Year EPS without NRI Growth Rate | 25.1 | |||||
| 3-Year FCF Growth Rate | 20.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 68.09 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.66 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.92 | |||||
| 9-Day RSI | 57.09 | |||||
| 14-Day RSI | 57.89 | |||||
| 3-1 Month Momentum % | 12.56 | |||||
| 6-1 Month Momentum % | 44.91 | |||||
| 12-1 Month Momentum % | 90.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | |||||
| Quick Ratio | 2.31 | |||||
| Cash Ratio | 1.96 | |||||
| Days Inventory | 192.46 | |||||
| Days Sales Outstanding | 81.81 | |||||
| Days Payable | 112.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.1 | |||||
| Shareholder Yield % | 3.72 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.89 | |||||
| Operating Margin % | -18.19 | |||||
| Net Margin % | -45.03 | |||||
| FCF Margin % | -22.41 | |||||
| ROA % | -19.85 | |||||
| ROIC % | -15.92 | |||||
| 3-Year ROIIC % | -39.66 | |||||
| ROC (Joel Greenblatt) % | -135 | |||||
| ROCE % | -15.89 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.26 | |||||
| EV-to-EBIT | -29.03 | |||||
| EV-to-Forward-EBIT | 5.79 | |||||
| EV-to-EBITDA | -47.25 | |||||
| EV-to-Forward-EBITDA | 5.63 | |||||
| EV-to-Revenue | 7.06 | |||||
| EV-to-Forward-Revenue | 4.53 | |||||
| EV-to-FCF | -31.29 | |||||
| Price-to-GF-Value | 1.38 | |||||
| Price-to-Median-PS-Value | 0.87 | |||||
| Earnings Yield (Greenblatt) % | -3.44 | |||||
| FCF Yield % | -4.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PTC Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 747.64 | ||
| EPS (TTM) (€) | -4.366 | ||
| Beta | 0.93 | ||
| 3-Year Sharpe Ratio | 0.51 | ||
| 3-Year Sortino Ratio | 0.74 | ||
| Volatility % | 20.83 | ||
| 14-Day RSI | 57.89 | ||
| 14-Day ATR (€) | 0.94002 | ||
| 20-Day SMA (€) | 50.11 | ||
| 12-1 Month Momentum % | 90.55 | ||
| 52-Week Range (€) | 22.4 - 53 | ||
| Shares Outstanding (Mil) | 78.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PTC Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PTC Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
PTC Therapeutics Inc Frequently Asked Questions
What is PTC Therapeutics Inc(FRA:BH3)'s stock price today?
The current price of FRA:BH3 is €51.50. The 52 week high of FRA:BH3 is €53.00 and 52 week low is €22.40.
When is next earnings date of PTC Therapeutics Inc(FRA:BH3)?
The next earnings date of PTC Therapeutics Inc(FRA:BH3) is 2025-04-25 Est..
Does PTC Therapeutics Inc(FRA:BH3) pay dividends? If so, how much?
PTC Therapeutics Inc(FRA:BH3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers